Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches.

Summary of "Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches."


Indacaterol is a once-daily long-acting inhaled beta2-agonist indicated for maintenance treatment of moderate-to-severe chronic obstructive pulmonary disease (COPD). The large inter-patient and inter-study variability in forced expiratory volume in 1 second (FEV1) with bronchodilators makes determination of optimal doses difficult in conventional dose-ranging studies. We considered alternative methods of analysis.
We utilized a novel modelling approach to provide a robust analysis of the bronchodilatory dose response to indacaterol. This involved pooled analysis of study-level data to characterize the bronchodilatory dose response, and nonlinear mixed-effects analysis of patient-level data to characterize the impact of baseline covariates.
The study-level analysis pooled summary statistics for each steady-state visit in 11 placebo-controlled studies. These study-level summaries encompassed data from 7476 patients at indacaterol doses of 18.75-600 ug once daily, and showed that doses of 75 ug and above achieved clinically important improvements in predicted trough FEV1 response. Indacaterol 75 ug achieved 74% of the maximum effect on trough FEV1, and exceeded the midpoint of the 100-140 mL range that represents the minimal clinically important difference (MCID; [greater than or equal to]120 mL vs placebo), with a 90% probability that the mean improvement vs placebo exceeded the MCID. Indacaterol 150 ug achieved 85% of the model-predicted maximum effect on trough FEV1 and was numerically superior to all comparators (99.9% probability of exceeding MCID). Indacaterol 300 ug was the lowest dose that achieved the model-predicted maximum trough response. The patient-level analysis included data from 1835 patients from two dose-ranging studies of indacaterol 18.75-600 ug once daily. This analysis provided a characterization of dose response consistent with the study-level analysis, and demonstrated that disease severity, as captured by baseline FEV1, significantly affects the dose response, indicating that patients with more severe COPD require higher doses to achieve optimal bronchodilation.
Comprehensive assessment of the bronchodilatory dose response of indacaterol in COPD patients provided a robust confirmation that 75 ug is the minimum effective dose, and that 150 and 300 ug are expected to provide optimal bronchodilation, particularly in patients with severe disease.


Journal Details

This article was published in the following journal.

Name: Respiratory research
ISSN: 1465-993X
Pages: 54


DeepDyve research library

PubMed Articles [45730 Associated PubMed Articles listed on BioPortfolio]

Pharmacokinetics of indacaterol and mometasone furoate delivered alone or in a free or fixed dose combination in healthy subjects.

QMF149 is a fixed-dose combination of the long-acting β2 agonist, indacaterol and the corticosteroid, mometasone furoate that is currently under development for treatment of patients with asthma and ...

FLIGHT: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrollate) Versus its Monocomponents and Placebo in Patients with COPD.

Current GOLD strategy recommends the combination of two long-acting bronchodilators of different pharmacological classes for the management of chronic obstructive pulmonary disease (COPD) if symptoms ...

Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.

Fludarabine, cyclophosphamide, and rituximab (FCR) result in durable responses in patients with previously untreated chronic lymphocytic leukemia (CLL). Previous reports have suggested that in patient...

A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies.

Dosing guidelines for immunoglobulin treatment in neurological disorders do not consider variations in immunoglobulin half-life or between patients. Individualisation of therapy could optimize clinica...

Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial.

The fixed-dose, long-acting bronchodilator combination of umeclidinium/vilanterol (UMEC/VI) has not previously been compared with a combination of a long-acting muscarinic antagonist and long-acting ...

Clinical Trials [10513 Associated Clinical Trials listed on BioPortfolio]

Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) in Chronic Obstructive Pulmonary Disease (COPD)

The study is designed to obtain safety and efficacy data on three dose levels of indacaterol when delivered via an SDDPI in patients with COPD. All patients will receive 1 day of treatment...

Dose Ranging Study of Indacaterol in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)

The study is designed to obtain data about the efficacy and safety of three doses of indacaterol (150, 300 and 600 µg) in Japanese patients with COPD so that optimal dose(s) can be chosen...

Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)

This study compares the 14-day bronchodilator efficacy of indacaterol with that of placebo and salmeterol.

26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Stage 1 of the study is designed to provide data about the risk-benefit of 4 dose regimens of indacaterol (75, 150, 300 & 600 µg o.d.) in order to select two doses to carry forward into s...

Efficacy, Safety and Tolerability of Once-daily (o.d.) Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily (b.i.d.) as Active Control

This study is designed to assess the efficacy and long-term safety data for the 300 and 600 µg doses of indacaterol when delivered via a single dose dry powder inhaler (SDDPI) in patients...

Medical and Biotech [MESH] Definitions

A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.

The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (from Lewis Dictionary of Toxicology, 1st ed)

The relationship between the dose of administered radiation and the response of the organism or tissue to the radiation.

The relationship between the dose of an administered drug and the response of the organism to the drug.

The dose amount of poisonous or toxic substance or dose of ionizing radiation required to kill 50% of the tested population.

Quick Search

DeepDyve research library

Relevant Topics

COPD (chronic obstructive pulmonary disease)
COPD (chronic obstructive pulmonary disease) is used for a number of conditions including chronic bronchitis and emphysema, which all  lead to the airways in the lungs becoming damaged and thus narrower,  making inhalation and exhalation harder...

Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Searches Linking to this Article